☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
migraine
Pfizer Signs a Commercialization Arrangement with Biohaven for Rimegepant to Treat Migraine
November 10, 2021
Amgen Reports Results of Aimovig (erenumab-aooe) in P-lV Study for the Treatment of Episodic and Chronic Migraine
November 9, 2021
AbbVie's Qulipta (atogepant) Receives the US FDA's Approval for the Treatment of Migraine
September 29, 2021
Impel NeuroPharma's Trudhesa (dihydroergotamine mesylate) Nasal Spray Receives the US FDA's Approval for the Treatment of Migraine
September 7, 2021
AbbVie Publishes 12-week Results of Atogepant in P-III ADVANCE Trial for the Preventive of Migraine in NEJM
August 19, 2021
Lundbeck Presents Results of Vyepti (eptinezumab-jjmr) in RELIEF Study for Preventive Treatment of Migraine at JAMA
June 16, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.